Dr Howard Weiner from the Harvard Medical School and Tiziana Life Sciences PLC’s (LON:TILS) (NASDAQ:TLSA) scientific advisory board chairman speaks to Proactive’s Andrew Scott following the news they’ve completed the clinical trial of its nasally administered Foralumab for the treatment of COVID-19 patients in Brazil. He says anecdotal feedback from Foralumab-treated patients has been positive and suggests the treatment was well-tolerated. Dr Weiner adds that the scientific approaches taken in this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses The last patients in the trial received their final dose on 21 December 2020. The topline data from the trial is expected to be available later this month.
Related Posts
